Parkinson's Institute and Clinical Center Appoints Dr. Salima Brillman to Medical Staff

Dec. 16, 2015 - PRLog -- The Parkinson’s Institute and Clinical Center (PI) announces the appointment of Salima Brillman, MD, to their medical staff effective today. Dr. Brillman is a bilingual board-certified Neurologist and Movement Disorders Specialist with over nine years of experience devoted to diagnosing and managing patients with Parkinson’s disease and other movement disorders. She has particular expertise in the use of Botulinum toxin, Deep Brain Stimulation and Neurogenic Orthostatic Hypotension.

Complementary to the mission of the Parkinson’s Institute and Clinical Center, Dr. Brillman recognizes the importance of dedicating time and education to the Parkinson’s disease population and their families. Upon realizing her aspiration to become a Neurologist, Dr. Brillman enrolled in Columbia University’s Post-Bac Pre-Med program and thereafter matriculated at the Universidad Autonoma de Guadalajara in Mexico. Upon graduation, Dr. Brillman prepared for a residency through the Fifth Pathway at New York Medical College. She then moved to Pittsburgh for her residency and fellowship at Allegheny General Hospital (AGH).

Following completion of her fellowship at AGH, Dr. Brillman moved to Bismarck, ND, where she was one of the founders of the only Deep Brain Stimulation program in North Dakota. Most recently, Dr. Brillman worked at the Parkinson’s Disease and Movement Disorders Center of Boca Raton (PDMDC). At PDMDC she gained considerable experience in clinical research as a sub-investigator in several trials including the Levodopa intestinal gel infusion study (Duopa™ which was FDA approved in April 2015).

Dr. Carrolee Barlow, CEO of the PI states, “Dr. Brillman is an integral addition to our medical staff, which includes leading physicians such as Dr. Rohit Dhall, Dr. Rita Gandhy, and Dr. William Langston as well as our outstanding physical therapist Barbara Luedtke and speech therapist Randy Hoffman. Dr. Brillman will serve as  Principal Investigator on the Lundbeck Neurogenic Orthostatic Hypotension Clinical Study and the Parkinson’s Progression Markers Initiative (PPMI) Clinical Study where she will be supported by our talented nurses and clinic staff. This word-class clinical team, combined with the work of our dedicated research physicians, Dr. Linda Rees and Dr. Birgitt Schuele, in addition to our basic science research teams, rounds out our unique model of research and care for Parkinson’s patients.”  Visit www.parkinsonsinstitute.org for a comprehensive professional bio on Dr. Brillman.